Showing 1 - 4 results of 4 for search 'Manjunath Krishnappa', query time: 0.02s Refine Results
  1. 1
    Addressing Irreversibility and Structural Distortion in WS2 Inorganic Fullerene-Like Nanoparticles: Effects of Voltage Cutoff Experiments in Beyond Li+‑Ion Storage Applications

    Addressing Irreversibility and Structural Distortion in WS2 Inorganic Fullerene-Like Nanoparticles: Effects of Voltage Cutoff Experiments in Beyond Li+‑Ion Storage Applications by Sonjoy Dey, Arijit Roy, Shakir Bin Mujib, Manjunath Krishnappa, Alla Zak, Gurpreet Singh

    Published 2024-04-01
    Get full text
    Article
  2. 2
    Antifungal Potential of <i>Azotobacter salinestris</i> Strain <i>Azt</i> 31 against Phytopathogenic <i>Fusarium</i> spp. Associated with Cereals

    Antifungal Potential of <i>Azotobacter salinestris</i> Strain <i>Azt</i> 31 against Phytopathogenic <i>Fusarium</i> spp. Associated with Cereals by Hanumanthu Nagaraja, Gurikar Chennappa, Nagaraj Deepa, Manjunath Krishnappa Naik, Kadaiah Ajithkumar, Yatgal Sharanappa Amaresh, Premila N. Achar, M. Y. Sreenivasa

    Published 2022-04-01
    Get full text
    Article
  3. 3
    Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

    Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double bli... by Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar

    Published 2020-06-01
    Get full text
    Article
  4. 4
    P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

    P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES by Manjunath Krishnappa, Divyesh Mandavia, Minish Jain, Mukesh S, Ankit Patel, Anshul Agarwal, Sanjeev Giri, Nirbhay Kumar Tiwari, Saravanan Thiyagarajan, Mamon Dey, Gutta Padmanabha Naidu, Murali Ramachandra, Akhil Kumar

    Published 2023-08-01
    Get full text
    Article

Search Tools: